Full Press Release Details
IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI ML Enabled Drug Discovery for Unprecedented First in Class Oncology Targets.
IDYA
IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI ML Enabled Drug Discovery for Unprecedented First in Class Oncology Targets
Key Takeaway: IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI ML Enabled Drug Discovery for Unprecedented First in Class Oncology Targets
Price reaction · baseline $20.57 (2025-02-28 close) · clean, no other IDYA news in the window
day 0 close
-7%
day 1 · peak
-8.7%
day 3
-7.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma